Dual Glucagon/GLP-1 Agonist Survodutide Produces Greater Weight Loss Than Semaglutide in Phase II Type 2 Diabetes Trial

Survodutide produced dose-dependent HbA1c reductions up to -1.71% (DG3, 1.8 mg weekly) and weight loss up to -8.7% (DG6, 1.8 mg twice weekly) over 16 weeks. At lower doses, survodutide matched semaglutide for HbA1c reduction (-1.46% vs. -1.47%). At higher doses, survodutide produced significantly greater weight loss than semaglutide (-8.7% vs. -5.3%). Gastrointestinal adverse events were the most common side effects, occurring in 77.8% of survodutide-treated participants versus 52% with semaglutide and 52.5% with placebo. A clear dose-response relationship was observed for both efficacy and adverse events.

Phase II, multicentre, randomized, double-blind, parallel-group, placebo-controlled trial with an open-label semaglutide comparator arm. 413 participants aged 18-75 with type 2 diabetes (HbA1c 7.0-10.0%), BMI 25-50 kg/m², on background metformin. Six survodutide dose groups (0.3-2.7 mg weekly or 1.2-1.8 mg twice weekly), one semaglutide arm (up to 1.0 mg weekly), and one placebo arm. Primary endpoint: HbA1c change at 16 weeks. Key secondary endpoint: bodyweight change at 16 weeks.

The addition of glucagon receptor agonism to GLP-1 signaling is a fundamentally different strategy from tirzepatide's GLP-1/GIP approach. Glucagon promotes energy expenditure and fat breakdown, which may explain survodutide's superior weight loss. This trial provides the first head-to-head data showing a dual glucagon/GLP-1 agonist outperforming semaglutide for weight loss in diabetic patients, supporting the glucagon agonism approach as a viable path to next-generation obesity treatment.

The incretin drug race now has three distinct strategies: GLP-1 monoagonism (semaglutide), GLP-1/GIP dual agonism (tirzepatide), and GLP-1/glucagon dual agonism (survodutide). Each exploits different metabolic pathways. Survodutide's glucagon component may produce superior weight loss through increased energy expenditure and fat mobilization, complementing GLP-1's appetite suppression. If the GI side effects can be managed, survodutide could become a powerful competitor in the rapidly expanding metabolic drug market.

This was a 16-week Phase II trial — too short to assess long-term efficacy, durability, or cardiovascular outcomes. The semaglutide arm was open-label (not blinded), introducing potential bias. The semaglutide dose was capped at 1.0 mg (not the 2.4 mg dose approved for obesity). GI adverse events were notably higher with survodutide, which could limit real-world adherence. The trial was funded by Boehringer Ingelheim, the manufacturer of survodutide.